Nyxoah (NYXH) Stock Price, News & Analysis

Company Overview

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient. Prior to bedtime, users apply the activation patch, which wirelessly powers the implant and delivers timed electrical pulses to the tongue muscles. Following a CE mark in 2019, Nyxoah initiated commercial launches across Europe and select international markets. The company is actively pursuing additional regulatory clearances, including a premarket application with the U.S. Food and Drug Administration, and is conducting ongoing clinical studies to expand the system’s indications and validate long-term safety and efficacy.

Building on its flagship product, Nyxoah continues to invest in research and development aimed at next-generation neuromodulation platforms for various sleep-related disorders. The company maintains a global footprint with commercial operations in Europe and a subsidiary in the United States, and collaborates with leading sleep centers to drive physician adoption and patient access. Nyxoah’s management team combines expertise in medical devices, sleep medicine, and implantable technologies to advance its mission of improving outcomes for patients suffering from obstructive sleep apnea.

Key Stats

• Today's Range: $1.64 to $1.70
• 50-Day Range: $1.31 to $1.78
• 52-Week Range: $1.26 to $6.87
• Volume: 39,201 shs
• Average Volume: 120,968 shs
• Market Capitalization: $63.57 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.26
• Consensus Rating: Hold

Nyxoah Stock Analysis - MarketRank™

Nyxoah scored higher than 55% of companies evaluated by MarketBeat, and ranked 422nd out of 914 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Hold

Consensus Rating

Nyxoah has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Nyxoah has a consensus price target of $4.26, representing about 159.9% upside from its current price of $1.64.

Amount of Analyst Coverage

Nyxoah has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Nyxoah are expected to grow in the coming year, from ($1.45) to ($0.80) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Nyxoah is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nyxoah is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nyxoah has a P/B Ratio of 0.66. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.13% of the float of Nyxoah has been sold short.

Short Interest Ratio / Days to Cover

Nyxoah has a short interest ratio ("days to cover") of 3.43, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nyxoah has recently increased by 6.24%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nyxoah does not currently pay a dividend.

Dividend Growth

Nyxoah does not have a long track record of dividend growth.

News and Social Media

• Score: 0.8 / 5
• News Sentiment: -0.69

News Sentiment

Nyxoah has a news sentiment score of -0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Nyxoah this week, compared to 3 articles on an average week.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Nyxoah insiders have not sold or bought any company stock.

Percentage Held by Insiders

17.11% of the stock of Nyxoah is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Nyxoah has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 8/20/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:NYXH
• CIK: 1857190
• Web: www.nyxoah.com
• Phone: 321-022-2355
• Fax: 321-045-9075
• Employees: 110
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Nyxoah: $4.26
• High Price Target: $6.00
• Low Price Target: $2.31
• Potential Upside/Downside: +159.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.52)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$101.92 million
• Net Margins: -443.16%
• Pretax Margin: -436.49%
• Return on Equity: -178.90%
• Return on Assets: -81.83%

Debt

• Debt-to-Equity Ratio: 0.44
• Current Ratio: 2.38
• Quick Ratio: 2.31

Sales & Book Value

• Annual Sales: $11.33 million
• Price / Sales: 5.61
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.49 per share
• Price / Book: 0.66

Miscellaneous

• Outstanding Shares: 38,760,000
• Free Float: 32,129,000
• Market Cap: $63.57 million
• Optionable: Not Optionable
• Beta: 1.62